Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Acta Neuropathol ; 127(6): 897-909, 2014.
Article in English | MEDLINE | ID: mdl-24777482

ABSTRACT

Diffuse intrinsic pontine glioma (DIPG), with a median survival of only 9 months, is the leading cause of pediatric brain cancer mortality. Dearth of tumor tissue for research has limited progress in this disease until recently. New experimental models for DIPG research are now emerging. To develop preclinical models of DIPG, two different methods were adopted: cells obtained at autopsy (1) were directly xenografted orthotopically into the pons of immunodeficient mice without an intervening cell culture step or (2) were first cultured in vitro and, upon successful expansion, injected in vivo. Both strategies resulted in pontine tumors histopathologically similar to the original human DIPG tumors. However, following the direct transplantation method all tumors proved to be composed of murine and not of human cells. This is in contrast to the indirect method that included initial in vitro culture and resulted in xenografts comprising human cells. Of note, direct injection of cells obtained postmortem from the pons and frontal lobe of human brains not affected by cancer did not give rise to neoplasms. The murine pontine tumors exhibited an immunophenotype similar to human DIPG, but were also positive for microglia/macrophage markers, such as CD45, CD68 and CD11b. Serial orthotopic injection of these murine cells results in lethal tumors in recipient mice. Direct injection of human DIPG cells in vivo can give rise to malignant murine tumors. This represents an important caveat for xenotransplantation models of DIPG. In contrast, an initial in vitro culture step can allow establishment of human orthotopic xenografts. The mechanism underlying this phenomenon observed with direct xenotransplantation remains an open question.


Subject(s)
Brain Stem Neoplasms , Disease Models, Animal , Glioma , Neoplasm Transplantation/methods , Animals , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Brain Stem Neoplasms/genetics , Brain Stem Neoplasms/pathology , Brain Stem Neoplasms/physiopathology , CD11b Antigen/metabolism , Cell Culture Techniques , Child , Female , Frontal Lobe/pathology , Frontal Lobe/physiopathology , Frontal Lobe/transplantation , Glioma/genetics , Glioma/pathology , Glioma/physiopathology , Humans , Infant , Leukocyte Common Antigens/metabolism , Male , Mice, Nude , Mice, SCID , Mice, Transgenic , Pons/pathology , Pons/physiopathology , Pons/transplantation , Young Adult
2.
PLoS One ; 8(4): e61512, 2013.
Article in English | MEDLINE | ID: mdl-23637844

ABSTRACT

Pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine gliomas (DIPG), are the leading cause of cancer-related death in children. While it is clear that surgery (if possible), and radiotherapy are beneficial for treatment, the role of chemotherapy for these tumors is still unclear. Therefore, we performed an in vitro drug screen on primary glioma cells, including three DIPG cultures, to determine drug sensitivity of these tumours, without the possible confounding effect of insufficient drug delivery. This screen revealed a high in vitro cytotoxicity for melphalan, doxorubicine, mitoxantrone, and BCNU, and for the novel, targeted agents vandetanib and bortezomib in pHGG and DIPG cells. We subsequently determined the expression of the drug efflux transporters P-gp, BCRP1, and MRP1 in glioma cultures and their corresponding tumor tissues. Results indicate the presence of P-gp, MRP1 and BCRP1 in the tumor vasculature, and expression of MRP1 in the glioma cells themselves. Our results show that pediatric glioma and DIPG tumors per se are not resistant to chemotherapy. Treatment failure observed in clinical trials, may rather be contributed to the presence of drug efflux transporters that constitute a first line of drug resistance located at the blood-brain barrier or other resistance mechanism. As such, we suggest that alternative ways of drug delivery may offer new possibilities for the treatment of pediatric high-grade glioma patients, and DIPG in particular.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Brain Stem Neoplasms/metabolism , Brain Stem Neoplasms/pathology , Drug Resistance, Neoplasm , Glioma/metabolism , Glioma/pathology , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Brain Stem Neoplasms/drug therapy , Child , Child, Preschool , Female , Gene Expression Regulation, Neoplastic/drug effects , Glioma/drug therapy , Humans , Infant , Infant, Newborn , Male , Neoplasm Grading
SELECTION OF CITATIONS
SEARCH DETAIL
...